Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furosemide + HSS in HFrEF
NCT04628325Phase 3Completed
- Sponsor
- University of Palermo
- Start
- Mar 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hypertonic saline in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by University of Palermo. Primary endpoints: N-terminal pro-B-type natriuretic peptide, Galectin-3 and 1 more. Started Mar 2017; status: completed.
02
Drugs
hypertonic saline
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT04628325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04628325.